Predictors for sarcopenia in biliary tract cancer patients

Article Sidebar

PDF
Published: Oct 25, 2022
DOI: https://doi.org/10.14456/apst.2022.86
Keywords:
Body composition Cholangiocarcinoma Fat-free mass Skeletal muscle mass Body imaging

Main Article Content

Prin Twinprai
Department of Radiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
Punthip Thammaroj
Department of Radiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
Julaluck Promsorn
Department of Radiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
Panita Limpawattana
Division of Geriatric Medicine, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
Kittisak Sawanyawisuth
Division of Ambulatory Medicine, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
Daris Theerakulpisut
Nuclear Medicine Division, Department of Radiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
Jarin Chindaprasirt
Medical Oncology Division, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Thailand

Abstract

Here, we report the clinical predictors for sarcopenia. Sarcopenia is a common condition in patients with cancer and is associated with treatment toxicity and poorer outcomes. However, there are limited data available on its differential clinical features in biliary tract cancer (BTC) patients with and without sarcopenia. Our primary analysis showed that decreased muscle mass was associated with shorter overall survival. This was a retrospective analysis of a prospective cohort of BTC patients who received chemotherapy between January 2016 and December 2017. Factors associated with sarcopenia were examined using uni- and multivariate logistic regression. During the study period, a total of 71 participants, including 45 with sarcopenia (63%) and 26 without sarcopenia (27%), were included. Four significant factors differed between those with and without sarcopenia including age (61.9 vs 55.3 years), the proportion of male patients (87% vs 65%), body mass index (20.6 vs 23.2 kg/m2), and skeletal muscle density (53.9 vs 59.2 HU). There were two independent predictors for sarcopenia in BTC patients: body mass index (BMI) and skeletal muscle density, with adjusted odds ratios (95% confidence interval) of 0.683 (0.530, 0.880) and 0.811 (0.700-0.944), respectively. Our study concludes that low body mass index and low skeletal muscle density on computed tomography (CT) imaging are suggestive of sarcopenia in biliary tract cancer patients.

Article Details

How to Cite
Twinprai, P., Thammaroj, P., Promsorn, J., Limpawattana, P., Sawanyawisuth, K., Theerakulpisut, D., & Chindaprasirt, J. (2022). Predictors for sarcopenia in biliary tract cancer patients. Asia-Pacific Journal of Science and Technology, 27(06), APST–27. https://doi.org/10.14456/apst.2022.86
Issue
Vol. 27 No. 06 (2022): NOV-DEC
Section
Research Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian working group for sarcopenia. J Am Med Dir Assoc. 2014;15(2):95-101.

Jentoft CAJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412-423.

Jentoft CAJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601.

Cipolli CG, Yassuda SM, Aprahamian I. Sarcopenia is associated with cognitive impairment in older adults: a systematic review and meta-analysis. J Nutr Health Aging. 2019;23(6):525-531.

Yeung SSY, Reijnierse EM, Pham VK, Trappenburg MC, Lim WK, Meskers CGM et al. Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10(3):485-500.

Chindapasirt J. Sarcopenia in cancer patients. Asian Pac J Cancer Prev. 2015;16(18):8075-8077.

Chung E, Lee HS, Cho ES, Park EJ, Baik SH, Lee KY et al. Prognostic significance of sarcopenia and skeletal muscle mass change during preoperative chemoradiotherapy in locally advanced rectal cancer. Clin Nutr. 2020;39(3):820-828.

Dolan RD, Almasaudi AS, Dieu LB, Horgan PG, McSorley ST, McMillan DC. The relationship between computed tomography-derived body composition, systemic inflammatory response, and survival in patients undergoing surgery for colorectal cancer. J Cachexia Sarcopenia Muscle. 2019;10(1):111-122.

Ganju RG, Morse R, Hoover A, Tennapel M, Lominska CE. The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation. Radiother Oncol. 2019;137:117-124.

Kamarajah SK, Bundred J, Tan BHL. Body composition assessment and sarcopenia in patients with gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22(1):10-22.

Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997-1006.

Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58-67.

Zhang XM, Dou QL, Zeng Y, Yang Y, Cheng ASK, Zhang WW. Sarcopenia as a predictor of mortality in women with breast cancer: a meta-analysis and systematic review. BMC Cancer. 2020;20(1):172.

Aubrey J, Esfandiari N, Baracos VE, Buteau FA, Frenette J, Putman CT, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol (Oxf). 2014;210(3):489-497.

Miljkovic I, Zmuda JM. Epidemiology of myosteatosis. Curr Opin Clin Nutr Metab Care. 2010;13(3):260-264.

Antoun S, Lanoy E, Iacovelli R, Sauvin AL, Loriot Y, Taoufik MM, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013;119(18):3377-3384.

Hayashi N, Ando Y, Gyawali B, Shimokata T, Maeda O, Fukaya M, et al. Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer. Oncol Rep. 2016;35(3):1727-1731.

Xiao J, Caan BJ, Feliciano CEM, Meyerhardt JA, Kroenke CH, Baracos VE, et al. The association of medical and demographic characteristics with sarcopenia and low muscle radiodensity in patients with nonmetastatic colorectal cancer. Am J Clin Nutr. 2019;109(3):615-625.

Limpawattana P, Theerakulpisut D, Wirasorn K, Sookprasert A, Khuntikeo N, Chindaprasirt J. The impact of skeletal muscle mass on survival outcome in biliary tract cancer patients. PLoS One. 2018;13(10): e0204985. PMID: 30303998.

Yoon SB, Choi MH, Song M, Lee JH, Lee IS, Lee MA, et al. Impact of preoperative body compositions on survival following resection of biliary tract cancer. J Cachexia Sarcopenia Muscle. 2019;10(4):794-802.

Lee BM, Cho Y, Kim JW, Jeung HC, Lee IJ. Prognostic significance of sarcopenia in advanced biliary tract cancer patients. Front Oncol. 2020;10:1581.

Kang J, Lee SH, Son JH, Lee JW, Choi YH, Choi JH, et al. Body mass index and weight change during initial period of chemotherapy affect survival outcome in advanced biliary tract cancer patients. PLoS One. 2018;13(4):e0195118. PMID: 29608578.

Limpawattana P, Inthasuwan P, Putraveephong S, Boonsawat W, Theerakulpisut D, Sawanyawisuth K. Sarcopenia in chronic obstructive pulmonary disease: a study of prevalence and associated factors in the Southeast Asian population. Chron Respir Dis. 2018;15(3):250-257.

Nasimi N, Dabbaghmanesh MH, Sohrabi Z. Nutritional status and body fat mass: determinants of sarcopenia in community-dwelling older adults. Exp Gerontol. 2019;122:67-73.

Sugawara K, Yamashita H, Okumura Y, Yagi K, Yoshimura S, Kawasaki K, et al. Relationships among body composition, muscle strength, and sarcopenia in esophageal squamous cell carcinoma patients. Support Care Cancer. 2020;28(6):2797-2803.

Carneiro IP, Mazurak VC, Prado CM. Clinical implications of sarcopenic obesity in cancer. Curr Oncol Rep. 2016;18(10):62.

Pongchaiyakul C, Limpawattana P, Kotruchin P, Rajatanavin R. Prevalence of sarcopenia and associated factors among Thai population. J Bone Miner Metab. 2013;31(3):346-350.

Caan BJ, Feliciano CEM, Prado CM, Alexeeff S, Kroenke CH, Bradshaw P, et al. Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol. 2018;4(6):798-804.

Kroenke CH, Prado CM, Meyerhardt JA, Weltzien EK, Xiao J, Feliciano CEM, et al. Muscle radiodensity and mortality in patients with colorectal cancer. Cancer. 2018;124(14):3008-3015.

Feliciano EMC, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML, et al. Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C scans study. Jama Oncol. 2017;3(12):e172319. PMID: 28796857.

Aust S, Knogler T, Pils D, Obermayr E, Reinthaller A, Zahn L, et al. Skeletal muscle depletion and markers for cancer cachexia are strong prognostic factors in epithelial ovarian cancer. PLoS One. 2015;10(10):e0140403. PMID: 26457674.

Weinberg MS, Shachar SS, Muss HB, Deal AM, Popuri K, Yu H, et al. Beyond sarcopenia: characterization and integration of skeletal muscle quantity and radiodensity in a curable breast cancer population. Breast J. 2018;24(3):278-284.